Skip to main content

The SCF Ubiquitin Ligases Involved in Hematopoietic Lineage

Buy Article:

$68.00 + tax (Refund Policy)

The ubiquitin-proteasome system is involved in various cellular functions by regulating protein degradation. It has been shown previously that the SCF-type ubiquitin (E3) ligases are involved in cell cycle control. Here we review E3 ligases playing the crucial roles in the determination of cell fate during hematopoiesis. SCFSkp2 controls the degradation of CDK inhibitors, such as p21, p27 and p57, to regulate hematopoietic stem cell lineage. SCFFbw7 targets several important proteins involved in hematopoiesis such as c-Myc, Notch and c-Myb. By controlling the precise levels of these proteins, E3 ligases are required for accurately determining hematopoietic lineage.

Keywords: E3 ligase; Fbw1; Fbw7; Hematopoietic stem cells; SCF complex; Skp2; Ubiquitin; hematopoiesis; phosphorylation; proteasome

Document Type: Research Article

Publication date: 01 December 2012

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content